Table 1.
Characteristics at enrollment survey and side effects of COVID-19 vaccines reported by participants at the first or second vaccine dose, by self-reported diabetic status.
|
|
All participants (N=7141) | ||
|
|
People with diabetes (n=724) | No reported diabetes (n=6417) | |
| Days of follow-up from completion of COVID-19 vaccine regimen (ie, last dose in regimen), n | 724 | 6417 | |
|
|
Mean (SD) | 182.1 (144.4) | 175.0 (143.9) |
|
|
Median (IQR) | 170.0 (38.0-319.5) | 145 (37.0-314.0) |
|
|
Range | 0-598.0 | 0-747.0 |
| Age (years), n | 724 | 6417 | |
|
|
Mean (SD) | 57.8 (12.04) | 47.5 (15.57) |
|
|
Median (IQR) | 60 (51.0-66.0) | 46 (34.0-61.0) |
| Age group (years), n | 724 | 6417 | |
|
|
18-29, n (%) | 14 (1.9) | 767 (12.0) |
|
|
30-39, n (%) | 46 (6.4) | 1704 (26.6) |
|
|
40-49, n (%) | 106 (14.6) | 1013 (15.8) |
|
|
50-59, n (%) | 193 (26.7) | 1104 (17.2) |
|
|
>60, n (%) | 365 (50.4) | 1829 (28.5) |
| Gender , n | 724 | 6417 | |
|
|
Self-described as female, n (%) | 552 (76.2) | 5375 (83.8) |
| Race, n | 724 | 6409 | |
|
|
Black, n (%) | 19 (2.6) | 100 (1.6) |
|
|
White, n (%) | 651 (89.9) | 5793 (90.4) |
|
|
Other, n (%) | 54 (7.5) | 516 (8.1) |
| Ethnicity, n | 720 | 6402 | |
|
|
Hispanic or Latino, n (%) | 39 (5.4) | 369 (5.8) |
| BMI, n | 714 | 6286 | |
|
|
Underweight or normal weight (15.0≤BMI<25.0), n (%) | 66 (9.2) | 1802 (28.7) |
|
|
Overweight (25.0≤BMI<30.0), n (%) | 150 (21.0) | 1825 (29.0) |
|
|
Obese (30.0≤BMI≤40.0), n (%) | 323 (45.2) | 2026 (32.2) |
|
|
Severe obesity (BMI>40.0), n (%) | 175 (24.5) | 633 (10.1) |
| Education, n | 720 | 6406 | |
|
|
High school or less, n (%) | 89 (12.4) | 525 (8.2) |
|
|
Some college, n (%) | 273 (37.9) | 1845 (28.8) |
|
|
4 year college degree, n (%) | 140 (19.4) | 1731 (27.0) |
|
|
>4 year college degree, n (%) | 218 (30.3) | 2305 (36.0) |
| Smoker, n | 671 | 6181 | |
|
|
Yes, n (%) | 73 (10.9) | 571 (9.2) |
| Vaccinated for influenza, n | 721 | 6358 | |
|
|
Yes, n (%) | 568 (78.8) | 4659 (73.3) |
| Other medical conditions, n | 724 | 6410 | |
|
|
Hypertension, n (%) | 409 (56.5) | 1286 (20.1) |
|
|
Depression, n (%) | 294 (40.6) | 2007 (31.3) |
|
|
Insomnia or trouble sleeping, n (%) | 275 (38.0) | 1889 (29.5) |
|
|
Anxiety, n (%) | 272 (37.6) | 2515 (39.2) |
|
|
Autoimmune disease, n (%) | 146 (20.2) | 732 (11.4) |
|
|
Cardiovascular disease, n (%) | 129 (17.8) | 311 (4.9) |
|
|
Lung disease, n (%) | 113 (15.6) | 585 (9.1) |
|
|
Kidney disease, n (%) | 70 (9.7) | 176 (2.7) |
|
|
Blood disorder, n (%) | 36 (5.0) | 150 (2.3) |
| Manufacturer of COVID-19 vaccine received, n | 724 | 6417 | |
|
|
Pfizer, n (%) | 327 (45.2) | 3124 (48.7) |
|
|
Moderna, n (%) | 317 (43.8) | 2502 (39.0) |
|
|
J&J, n (%) | 80 (11.0) | 791 (12.3) |
| Categories of number of side effects to COVID-19 vaccines, n | 724 | 6417 | |
|
|
No side effects, n (%) | 93 (12.8) | 530 (8.3) |
|
|
1 to 2 side effects, n (%) | 300 (41.4) | 2186 (34.1) |
|
|
3 or more side effects, n (%) | 331 (45.7) | 3701 (57.7) |
| Number of side effects to COVID-19 vaccines, n | 724 | 6417 | |
|
|
Mean (SD) | 2.7 (2.0) | 3.1 (2.0) |
|
|
Median (IQR) | 2 (1.0-4.0) | 3 (2.0-5.0) |
|
|
Range | 0-9 | 0-10 |
| Specific side effects to COVID-19 vaccines, n | 724 | 6417 | |
|
|
Injection site reactions, n (%) | 530 (73.2) | 4995 (77.8) |
|
|
Fatigue, n (%) | 435 (60.1) | 4484 (69.9) |
|
|
Headache, n (%) | 284 (39.2) | 3126 (48.7) |
|
|
New or worsening muscle pain, n (%) | 177 (24.4) | 1928 (30.0) |
|
|
Fever, n (%) | 171 (23.6) | 1938 (30.2) |
|
|
New or worsening joint pain, n (%) | 142 (19.6) | 1360 (21.2) |
|
|
Nausea or vomiting, n (%) | 91 (12.6) | 1016 (15.8) |
|
|
Swollen lymph nodes, n (%) | 71 (9.8) | 724 (11.3) |
|
|
Chills, n (%) | 20 (2.8) | 312 (4.9) |
|
|
Diarrheaa, n (%) | <10 | 72 (1.1) |
|
|
Dizzinessa, n (%) | <10 | 76 (1.2) |
|
|
Severe allergic reactiona, n (%) | <10 | 35 (0.5) |
aPercentage not shown for <10 responses.